Mesothelioma Treatment and Aggressive Debulking

A different interesting study is named, "Continuous hyperthermic peritoneal perfusion with cisplatin for the therapy of peritoneal mesothelioma." By Ma GY, Bartlett DL, Reed E, Figg WD, Lush RM, Lee KB, Libutti SK, Alexander HR. - Metabolism Section, National Cancer Institute, National Institutes of Well being, Bethesda, Maryland 20892.  Cancer J Sci Am. 1997 May perhaps-Jun3(three):174-9.  Here is an excerpt: "Abstract - PURPOSE: Peritoneal mesothelioma remains a tough therapeutic challenge. Aggressive debulking combined with continuous hyperthermic peritoneal perfusion (CHPP) employing cisplatin (CDDP) is a novel technique for the therapy of peritoneal mesothelioma, allowing high regional delivery of chemotherapeutics and hyperthermia whilst minimizing systemic toxicity. PATIENTS AND Methods: From June 1993 to May well 1996, 10 patients with peritoneal mesothelioma (six men, four females mean age 40 years, range 15-57) underwent tumor debulking followed by a 90-minute CHPP. CHPP parameters included mean initial CDDP of 120 micrograms/mL (range 81-166), perfusate volume five.two L (range four-7), flow 1.five L/min, intraperitoneal temperature at three locations-41.five degrees C, 40.five degrees C, 41.1 degrees C, and core temperature 38.4 degrees C (range 37.2 degrees C-39.five degrees C). Nine of 10 patients had malignant peritoneal mesothelioma, eight with related ascites, although the tenth had a symptomatic, multiply recurrent benign peritoneal mesothelioma. Nine of 10 patients were optimally debulked. Pharmacokinetics had been performed on blood and perfusate samples on nine patients CDDP levels had been quantitated by atomic absorption spectroscopy.  Outcomes: Total perfusate cisplatin AUC was a mean of 21-fold higher (range 2- to 116-fold) than total serum cisplatin AUC, and serum CDDP behaved similarly to systemically administered CDDP. Median follow-up after CHPP is 10 months (range two-32), with no treatment-related mortality. In eight optimally debulked patients there is no evidence of recurrent illness clinically or by CT or MRI. Seven patients with symptomatic ascites have been entirely palliated.

CONCLUSIONS: CHPP with CDDP is well tolerated with no significant regional toxicity. Because favorable CDDP pharmacokinetics recommend the potential for enhanced CDDP tumoricidal impact for the duration of CHPP, tumor debulking and CHPP may possibly represent an powerful method for the therapy of peritoneal mesothelioma.

A further interesting study is known as, "The diagnostic distinction in between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3)." by C. A. Szpak, W. W. Johnston, V. Roggli, J. Kolbeck, S. C. Lottich, R. Vollmer, A. Thor, and J. Schlom - Am J Pathol. 1986 February 122(two): 252–260.   Here is an excerpt: "Abstract - The correct distinction in between malignant mesothelioma of the pleura and adenocarcinoma of the lung has become increasingly complicated, with a variety of histochemical, immunohistochemical, and ultrastructural studies to be performed on biopsy material. The reliability of immunohistochemical studies has been hampered by the use of polyclonal antisera to "carcinoembryonic antigen (CEA)" and keratin. Hybridoma technology now delivers monoclonal antibodies (MAbs) in unlimited quantity and standardized good quality to selective ranges of specific antigenic determinants. MAb B72.three, generated against a membrane-enriched fraction of human metastatic breast carcinoma, was utilized to distinguish malignant mesothelioma of the pleura from adenocarcinoma of the lung in tissue sections and was compared in terms of diagnostic utility with polyclonal anti-keratin and anti-CEA to make the very same distinction. Reactivity with MAb B72.3 in at least 10% of tumor cells or extra was noted in 19 of 22 adenocarcinomas of the lung (P higher than .0001), whereas none of the 20 situations of malignant mesothelioma demonstrated comparable reactivity. Furthermore, MAb B72.three showed no reactivity with benign mesothelial proliferations. MAb B72.three thus appears to be an proper diagnostic adjunct capable of discriminating in between these malignancies."

We all owe a debt of gratitude to these fine researchers.  If you located any of these excerpts fascinating, please read the studies in their entirety.